Antibody treatments of inflammatory arthritis
Brown, Matthew A. (2005) Antibody treatments of inflammatory arthritis. Current Medicinal Chemistry, 12(25), pp. 2943-2946.
Inflammatory arthropathies such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis are extremely common in the community, with a prevalence of up to 5%, and they cause substantial morbidity. The development of anti-TNF agents for use initially in rheumatoid arthritis, and subsequently more broadly in inflammatory arthritis, represents the biggest advance in management of these conditions since the introduction of corticosteroid agents, and is a major vindication of public funded arthritis research. However, there are limitations of even these highly effective agents. A significant minority of patients with inflammatory arthritis do not respond to these anti-TNF agents, they are associated with substantial risk of toxicity, require parenteral administration, and are extremely expensive. New antibody treatments in development can be divided into anti-cytokine agents, cell-targeted therapies, co-stimulation inhibitors, and treatments aimed at preventing joint erosion consequent on inflammation. This review discusses the state of the art in the development of these agents for management of this common group of diseases.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||No file attached.|
|Keywords:||adalimumab, alemtuzumab, cd4 antibody, corticosteroid, cyclophosphamide, cytokine antibody, disease modifying antirheumatic drug, efalizumab, epratuzumab, interleukin 1 antibody, interleukin 6 antibody, methotrexate, placebo, recombinant interleukin 1 receptor blocking agent, rituximab, tumor necrosis factor antibody, unclassified drug, ankylosing spondylitis, arthritis, arthropathy, B lymphocyte, clinical trial, drug eruption, drug fatality, drug targeting, human, infection, lymphocytopenia, morbidity, prevalence, psoriatic arthritis, review, rheumatoid arthritis, side effect, Sjoegren syndrome, systemic lupus erythematosus, T cell depletion, Anti-Inflammatory Agents, Antibodies, B-Lymphocytes, Cytokines, Humans, Inflammation, Osteoporosis, T-Lymphocytes|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Deposited On:||02 Oct 2015 01:32|
|Last Modified:||18 Oct 2015 22:55|
Repository Staff Only: item control page